Sumary of Adding nivolumab to neoadjuvant chemotherapy does not impede surgery in resectable NSCLC:
- The addition of nivolumab to neoadjuvant chemotherapy appeared safe and did not impact timing or feasibility of surgery among patients with resectable non-small cell lung cancer, according to results of the phase 3 CheckMate 816 trial..
- The results, presented during the virtual ASCO Annual Meeting, also showed improvements in pathologic complete response regardless of disease stage with the addition of nivolumab (Opdivo, Bristol Myers Squibb) to chemotherapy..
- “Single-arm, phase 2 trials incorporating neoadjuvant checkpoint blockade have shown encouraging efficacy outcomes in terms of pathologic complete response, EFS and OS without compromising the feasibility of surgery for patients with resectable NSCLC,”.
- Jonathan Spicer, MD, assistant professor of surgery at McGill University and attending surgeon in the division of thoracic and upper gastrointestinal surgery at Montreal General Hospital in Canada, said during his presentation..
- Forde, MD, presented the first positive, independent primary endpoint from CheckMate 816 demonstrating significantly improved pathologic complete response after neoadjuvant nivolumab plus chemotherapy..
- Here, we present additional efficacy data segregated by disease stage, as well as key surgical outcomes from CheckMate 816.”.
- Pathologic complete response, defined as the absence of viable tumor cells in lung and lymph nodes, and EFS served as co-primary endpoints..
- “Results of the current study showed an improvement in pathologic complete response rates regardless of disease stage compared with chemotherapy alone.”…